NETTER-2 is a phase 3, randomized, open-label, active comparator, multicenter study of the efficacy of LUTATHERA with 30 mg octreotide LAR (n=151) vs 60 mg octreotide LAR (n=75) in patients with newly diagnosed, well-differentiated, grade 2/3 advanced SSTR+ GEP-NETs. SSA-naive patients were eligible, as well as patients previously treated with SSAs in the absence of progression. The primary end point of the study was centrally assessed PFS. The median PFS in the LUTATHERA arm was 22.8 months (95% CI, 19.4-NE) vs 8.5 months (95% CI, 7.7-13.8) in the control arm.1,4,*
NETTER-1 was a pivotal, phase 3, randomized, multicenter, open-label study of LUTATHERA with 30 mg octreotide LAR (n=116) vs 60 mg octreotide LAR (n=113) in patients with locally advanced, inoperable, or metastatic grade 1/2 SSTR+ GEP-NETs after progression on an SSA. The primary end point of the study was centrally assessed PFS. The median PFS in the LUTATHERA arm was not reached at primary analysis (95% CI, 18.4-NE) vs 8.5 months (95% CI, 6.0-9.1) in the control arm.2,3,5,*
*Defined as the time from randomization to first documented disease progression (centrally assessed according to RECIST v1.1) or death due to any cause.1
GEP-NETs, gastroenteropancreatic neuroendocrine tumors; LAR, long-acting release; NE, not evaluable; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors; SSA, somatostatin analogue; SSTR+, somatostatin receptor-positive.